Rizwan Haq MD PhD

Hematologic Oncology, Melanoma

Dana-Farber Cancer Institute, Harvard Medical School

450 Brookline AveBoston, MA 02215
Phone+1 617-632-5055

Dr. Haq is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Haq's full profile Already have an account?

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2006 - 2009
Johns Hopkins UniversityResidency, Internal Medicine, 2003 - 2006
University of Toronto Faculty of MedicineClass of 2003
University of Toronto Faculty of MedicineClass of 2003

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MA State Medical License 2008 - 2027
NH State Medical License 2024 - 2024
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2017
CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2013-2014, 2017
CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2013-2014, 2017

Clinical Trials

IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma Start of enrollment: 2020 Mar 16
COMPLETED
PHASE1
Roles: Contact
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma Start of enrollment: 2023 Oct 31
ACTIVE_NOT_RECRUITING
PHASE2, PHASE3
Roles: Contact

Publications & Presentations

PubMed

Oncogenic Gα signaling requires AP-3-dependent recruitment to the endolysosomal compartment.
Megha Shettigar, Salomé Moulière, Larissa Isenegger, Alexander L DeVine, Cécile Gstalder
Proceedings of the National Academy of Sciences of the United States of America. 2026-07-28
Meeting Report From the 2025 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Amsterdam, the Netherlands, October 2025.
Andrew E Aplin, Katherina Alsina, Allison S Betof, Joseph Birkett, Marcus O Butler
Pigment Cell & Melanoma Research. 2026-07-01
Radiation therapy, cytogenetic prognostication, novel systemic chemotherapy, and patient perspective in an adult with choroidal melanoma.
Kevin Card, Rizwan Haq, John Mignano, Shilpa J Desai
CA. 2026-06-10

Journal Articles

Genomic Correlates of Response to Immune Checkpoint Blockade in Microsatellite-Stable Solid Tumors
Jeffrey A Engelman, David A Barbie, Nicole G Chau, Glenn J Hanna, Natalie I Vokes, Sabina Signoretti, Pasi A Janne, Robert I Haddad, Lynette M Sholl, Rizwan Haq, Peter..., Nature